Launch of Bocipal, Hipular, Vadrox. Agreement with Biopharma

Launch of Gorax and Anfonax . Agreement with SINOVAC for Argentina and Peru.

Launching of Ultraciclib, Rupovar – Agreement with Biocon and Dr Reddy’s – Agreement with EUSA Pharma for Qarziba and Silvant - Agreement with Nanox for Nanotechnology Line.

Agreement with Recordati for Signifor, Signifor LAR – Expansion of Rare Diseases Line – Opening new subsidiaries: Uruguay, Paraguay. Expansion into the Rare Diseases and Hospital Products therapeutic area.

Agreement with Recordati for Ledaga – Launching of Funomid, Suprol.

Agreement with Aqvida and Aigen – Opening new subsidiaries: Chile, Perú, Ecuador - Launching of Lenvatib, Idelib Ponatib, Binap - Agreement with Adienne for Tepadina.

Agreement with Myriad Genetics for Endopredict – Expansion into the Genomic Tests therapeutic area.

Agreement with Amgen for LATAM Mvasi, Kanjinti.

Agreement with Amgen for Blincyto, Xgeva.

Agreement with Amgen for Neupogen, Neulastim, Aranesp.

Launching of Relotib – Agreement with Onyx/Amgen for Kyprolis

Argentina’s launching of Bendavar

Expansion into the Transplant therapeutic area

Agreement with Celgene for Vidaza - Expansion into the Oncohematology therapeutic area

Opening of our Plant Commissioning

Agreement with Octapharma for Blood Derivatives portfolio. Expansion into the Hematology therapeutic area.

Agreement with Cassará Lab for Biotechnological Line.